Lido Advisors LLC lifted its stake in Celgene Co. (NASDAQ:CELG) by 4.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,256 shares of the biopharmaceutical company’s stock after purchasing an additional 609 shares during the period. Lido Advisors LLC’s holdings in Celgene were worth $977,000 at the end of the most recent quarter.
Other institutional investors also recently modified their holdings of the company. Bruderman Asset Management LLC acquired a new stake in shares of Celgene in the fourth quarter valued at approximately $25,000. Murphy Pohlad Asset Management LLC acquired a new stake in shares of Celgene in the fourth quarter valued at approximately $25,000. Athena Capital Advisors LLC acquired a new stake in shares of Celgene in the fourth quarter valued at approximately $27,000. Berman Capital Advisors LLC acquired a new stake in shares of Celgene in the fourth quarter valued at approximately $32,000. Finally, Doyle Wealth Management acquired a new stake in shares of Celgene in the fourth quarter valued at approximately $44,000. 74.19% of the stock is owned by institutional investors and hedge funds.
A number of brokerages recently weighed in on CELG. Jefferies Financial Group lowered shares of Celgene from a “buy” rating to a “hold” rating and set a $95.00 price target for the company. in a report on Friday, February 1st. Wells Fargo & Co lowered their price target on shares of Celgene from $90.00 to $84.00 and set a “market perform” rating for the company in a report on Thursday, January 3rd. Cantor Fitzgerald reissued a “buy” rating and issued a $100.00 price target on shares of Celgene in a report on Thursday, January 3rd. Morgan Stanley lowered their target price on shares of Celgene from $93.00 to $88.00 and set an “equal weight” rating for the company in a report on Wednesday, December 19th. Finally, ValuEngine raised shares of Celgene from a “strong sell” rating to a “sell” rating in a report on Friday, January 4th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $100.94.
In other news, Director James J. Loughlin sold 23,466 shares of Celgene stock in a transaction on Thursday, February 7th. The shares were sold at an average price of $87.29, for a total transaction of $2,048,347.14. Following the transaction, the director now directly owns 62,102 shares of the company’s stock, valued at $5,420,883.58. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Ernest Mario purchased 2,000 shares of Celgene stock in a transaction dated Tuesday, February 12th. The shares were purchased at an average cost of $89.99 per share, for a total transaction of $179,980.00. The disclosure for this purchase can be found here. Company insiders own 0.39% of the company’s stock.
CELG opened at $88.46 on Friday. The company has a debt-to-equity ratio of 3.21, a current ratio of 2.23 and a quick ratio of 2.12. Celgene Co. has a 52 week low of $58.59 and a 52 week high of $95.30. The firm has a market cap of $62.13 billion, a price-to-earnings ratio of 11.62, a price-to-earnings-growth ratio of 0.39 and a beta of 1.69.
Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, January 31st. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping analysts’ consensus estimates of $2.32 by $0.07. The company had revenue of $4.04 billion for the quarter, compared to analysts’ expectations of $3.98 billion. Celgene had a net margin of 26.48% and a return on equity of 114.66%. During the same period last year, the firm posted $2.00 earnings per share. Equities analysts expect that Celgene Co. will post 10.01 EPS for the current year.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Story: Net Margin
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.